Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
Department
Adjust height of sidebar
KMap
Department
Senior VP Health Sciences
16 active people
114 grants
Recent Grants
A Phase I/II, Randomized, Double-blind, Sham Control Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Ascending Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gen
2024
·
$1.1M
gene therapy,
neurodegenerative diseases,
clinical trial,
genetic disorders,
drug safety
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have
2024
·
$964K
clinical trials,
dermatology,
immunology,
inflammatory diseases,
pharmacology
Study to Evaluate Safety, Efficacy and Tolerability of ABBV-950 for the Treatment of Upper Limb Spasticity in Adult Post-Stroke Patients
2024
·
$822.1K
stroke rehabilitation,
spasticity treatment,
drug safety,
efficacy evaluation,
tolerability assessment
A Randomized, Phase 2, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of KER-012 in Combination with Background Therapy in Adult Participants with Pulmonary Arterial Hyp
2024
·
$555.7K
clinical trials,
pulmonary arterial hypertension,
drug efficacy,
safety evaluation
A Phase 2b, Multinational, Randomized, Double-blind Study to Investigate the Efficacy and Safety of Redasemtide (S-005151) Compared With Placebo in Adult Participants With Acute Ischemic Stroke Who Ar
2024
·
$470.3K
stroke,
clinical trial,
medication,
safety,
efficacy
Protocol Title: A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in Subjects with Acute Ischemic Stroke (AIS)
2024
·
$370.5K
stroke,
drug efficacy,
safety evaluation,
clinical trial,
ischemic stroke
Diversity in Research Education in Aging Medicine and Science
2024
·
$288.3K
diversity,
education research,
aging,
medicine,
science
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-1)
2024
·
$277.3K
clinical trials,
autoimmune diseases,
medication efficacy,
safety assessment,
immunology
A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy And Safety of Belimumab Administered Subcutaneously in Adults With Systemic Sclerosis Associate
2024
·
$270.6K
autoimmune diseases,
clinical trials,
immunology,
rheumatology,
drug administration
A Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pln-74809 (Bexotegrast) for the Treatment of Idiopathic Pulmonary Fibrosis (BEACON-IPF)
2024
·
$221.6K
pulmonary fibrosis,
clinical trial,
drug efficacy,
safety evaluation
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of ABX464 Once Daily for Induction Treatment in Subjects With Moderately to Severely Act
2024
·
$133.3K
clinical trials,
inflammatory bowel disease,
drug efficacy,
safety evaluation
Data-Driven Population Health Surveillance at Scale for Pandemic Readiness
2024
·
$68K
population health,
data analysis,
pandemic preparedness,
surveillance,
data-driven approach
A Phase 2, multicenter, Open-Label, Long-Term Safety Study of LP352 in Subjects with Developmental and Epileptic Encephalopathy who Completed Study LP352-201 and are Candidates for Continuous Treatmen
2024
·
$19.8K
epileptic encephalopathy,
long-term safety,
developmental disorders
A Phase 2a, Double-Blind, Randomized Adaptive Design, Placebo-Controlled, Parallel Group Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Biomarkers with Oral Colon Delivery
2024
·
$2.6K
clinical trial,
pharmacokinetics,
drug delivery,
safety assessment,
biomarkers
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency?associated Liver Disease With Metavir
2023
·
$1.6M
clinical trial,
liver disease,
alpha-1 antitrypsin,
treatment,
safety
A First-in-human (FIH) Study of Inhibitory Interneurons (NRTX-1001) in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (MTLE)
2023
·
$749.8K
neuroscience,
epilepsy,
clinical trial,
drug resistance,
inhibitory interneurons
TRANSFORM: A 52-week, Randomized, Placebo-controlled, Double-blind, Adaptive Phase 2b/3 Trial of Setanaxib with a 52-week Extension Phase in Patients with Primary Biliary Cholangitis (PBC) and Elevate
2023
·
$641.6K
clinical trial,
drug therapy,
liver disease,
biomarker,
immunology
Phase 1/2a Dose Escalation Study of ANPD001 in Sporadic Parkinson Disease
2023
·
$597.6K
parkinson's disease,
dose escalation,
clinical trial,
neurodegenerative diseases
Randomized Phase 2 Study of DKN-01 Plus FOLFIRI/FOLFOX and Bevacizumab Versus FOLFIRI/FOLFOX and Bevacizumab as Second-line Treatment of Advanced Colorectal Cancer (DeFianCe)
2023
·
$568.2K
colorectal cancer,
treatment,
clinical trial,
dkn-01,
chemotherapy
A Phase 1b/2a Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy
2023
·
$543.6K
clinical trials,
pharmacology,
safety,
efficacy,
dose escalation
People
Alma Leon
Research Nurse III
Brent Gary
Clinical Research Coordinator II
Catherine Correia
Administrative Support Professional II
Daniel Duran
Clinical Research Coordinator I
Austin Derma
Clinical Research Coordinator II
David Elmer
Administrative Operations Manager V, Medicine
Gustavo Cornejo
Research Compliance Administrator II
Kaitlyn Ammann
Researcher/Scientist III
Kirsten Anderson
Research Compliance Administrator IV
Maria Ambrose
Research Specialist, Senior
Maria Gordon
Clinical Research Manager II
Matthew Briggs
Assistant Professor of Practice
Nirav Merchant
Research Program Administration Manager V
Pamela Ray
Financial Analysis Manager V
Tanyha Zepeda
Database Administrator III
Angela Souza
Campus Planning Manager IV
Research expenses history
Funding support
14 funding agencies since 2020